How Is Convatec Group Plc (LSE:CTEC) Trading Today?

Convatec Group Plc (LSE:CTEC) shares edged higher by 0.16% to around 256.2p today, as investors follow the group's progress towards faster growth in the second half of 2026.

First-half Revenue rose 4.4% to $1,232 million, with organic growth of 5% excluding InnovaMatrix. Adjusted operating profit rose 3.9% to $262 million, and the adjusted Operating Margin was 21.2%.

The board announced a $200 million share buyback and increased the Interim Dividend by 15.4% to 2.166 cents per share.

About Convatec Group Plc

Convatec is a global medical products and technologies company focused on chronic conditions. Its franchises include Advanced Wound Care, Ostomy Care, Continence and Critical Care and Infusion Care, including products for diabetes management.

The company serves patients, clinicians and healthcare systems worldwide, with products such as Aquacel dressings, GentleCath catheters and infusion sets.

LSE:CTEC therefore offers exposure to the long-term Demand for chronic care solutions in ageing populations.

H1 2026 Results

Management described delivery in the first half as on track, with growth in line with expectations and a clear plan for acceleration in the second half. Adjusted Earnings Per Share grew 6% and the operating margin was up 50 basis points at constant currency.

The company expects free Cash Flow conversion of around 100% for 2026, and a trading update for the ten months to 31 October is scheduled for 18 November 2026.

Growth was broad based across franchises and regions, with the group noting some order phasing in Aquacel that it expects to pick up in the second half, supporting Advanced Wound Care growth in the coming months.

Second-Half Acceleration

Convatec expects organic growth of 6% to 8% in the second half, led by Infusion Care, where double-digit growth is anticipated and high single-digit growth for the full year. Management said it holds purchase orders supporting this expectation.

Operating margin is expected to be materially higher in the second half, reaching about 25%, helped by a normal second-half revenue weighting, a favourable Infusion Care mix, additional trading days and productivity savings.

Medium-Term Targets

The group reiterated its goals of a mid-20s operating margin in 2027 and Organic Sales growth of 6% to 8% with double-digit earnings per share growth in each year thereafter. It upgraded its medium-term organic growth target to 6% to 8% in February.

Full-year 2025 results showed revenue up 6.5% to $2,439 million and adjusted diluted EPS up 16.0% to 17.6 cents.

Product Innovation

Convatec continues to introduce new products, including GentleCath Air for Women, which more than doubled year on year in the first half and contributed one percentage point to category growth. Capacity expansion is planned to support future demand, with most of the larger additions coming online from 2027.

The company invests in clinical evidence, digital tools and patient support to differentiate its offering.

Infusion Care benefits from demand for insulin pump infusion sets used by people with diabetes, while the Continence Franchise draws on intermittent catheter innovations designed to improve comfort and independence.

Capital Returns

The $200 million buyback is due to be completed by year end, and the interim dividend increase reflects confidence in cash generation. Net Debt to adjusted EBITDA was 2.3 times, with a target of around 2.0 times by year end.

Management has said further Capital would be available to increase Shareholder returns over time.

Cash conversion was influenced by normal seasonal Working Capital movements in the first half, which management expects to reverse in the second half, supporting full-year cash generation and the Balance Sheet target.

Growth Catalysts

Catalysts for LSE:CTEC include infusion set demand, continence innovation, wound care recovery and Operating Leverage from simplification. Demographic trends supporting chronic care may also provide a long-term tailwind.

Partnerships with healthcare providers and payers help broaden access to its products.

The ostomy franchise has a long record of recurring demand, and the company's Investment in digital engagement and patient support programmes helps to build loyalty and long-term relationships with patients and clinicians.

Factors to Monitor

Healthcare product companies are influenced by reimbursement, regulatory approvals, Supply chain conditions and currency movements. Half-on-half phasing can affect reported growth.

Investors typically follow organic growth, margin progress, cash conversion and updates at each reporting date.

Conclusion

Convatec's 0.16% gain to around 256.2p today follows first-half revenue of $1,232 million, a $200 million buyback and an expected acceleration in the second half.

Infusion Care, innovation, margins and capital returns remain the central themes for LSE:CTEC.